In Saudi Arabia, with over 32 million people and a growing healthcare industry, Admedus is now approved to sell their CardioCel biomaterial for heart valve repair surgeries and expand their Middle East presence. Admedus now sells CardioCel in many countries around the world and includes 135 medical centres, but Saudi Arabia is an important market for them since cardiovascular disease is the main cause of death in the country. They partnered with Genpharm for this expansion which is already active in Saudi Arabia and they are focusing on pediatric cardiac care first. The expansion is projected to keep Admedus on track for their anticipated $21 million revenue for the year. Wayne Paterson, CEO, told Proactive Investors, “This is the most significant approval for Admedus and our partners Genpharm in this key strategic region.”
Latest article
World Animal Protection launches AI-Powered cultivated meat chatbot
In London, animal advocacy group World Animal Protection has partnered with AI software company PubTrawlr to unveil Cultivator, the first-ever chatbot dedicated to cultivated...
DOE awards Hempitecture $8.42 million to boost hemp fiber manufacturing in Tennessee
In Idaho, sustainable building materials firm Hempitecture has been awarded $8.42 million in funding from the U.S. Department of Energy under the Biden-Harris Administration’s...
CJ Biomaterials PHA earns compostability certification
In Massachusetts, CJ Biomaterials, a division of South Korea's CJ CheilJedang, has received certification from the Biodegradable Products Institute (BPI) for its range of...